MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--InPress Technologies (InPress), a medical device company developing a quick and effective solution to postpartum hemorrhage (PPH), has announced the successful completion of its first human trial conducted at three medical centers in Jakarta, Indonesia: Dr. Cipto Mangunkusumo Hospital (RSCM), RSIA Budi Kemuliaan (RSIA) and Fatmawati General Hospital (RSUP). In the study of 10 patients, hemorrhage control was initiated within two minutes of the InPress device placement and full control reached in just over two hours on average. This is significant because similar devices designed to treat PPH require from 10 to 24 hours to reach full hemorrhage control.
The “First in Woman” clinical investigation began enrolling patients in July 2014, after InPress received the “Lefteroff Innovator Award” from the Fogarty Institute for Innovation (FII). Named in honor of Tracy Lefteroff, the award directly funds projects for promising new innovators working on pre-screened medical ideas. InPress is a company-in-residence at the prestigious FII, a Silicon Valley-based catalyst for medical device innovation that provides intellectual and physical resources to early-stage innovators whose ideas have significant technical merit and a high potential of improving the lives of people around the world.
“In less than nine months, we funded and completed our first human study with encouraging results,” said Jessie Becker, co-founder and CEO of InPress Technologies. “This initial clinical validation is a major accomplishment, and puts us one step closer to making our proprietary device part of the standard procedure for childbirth around the world.”
PPH is excessive bleeding in a mother after childbirth and the leading cause of perinatal maternal death around the world. Clinically, 80 percent of the instances of PPH are caused by failure of the uterus to contract after childbirth. Known as uterine atony, this leaves the blood vessels fully dilated and allows unobstructed bleeding. Pharmaceuticals are often used to treat PPH, but they only address its symptoms. The non-invasive InPress device is designed to solve the most common underlying cause of PPH by producing an immediate, vacuum-induced tamponade effect that results in normal postpartum uterine contractions over time.
“The InPress device is unique, as it works with the body to encourage the body’s natural response to PPH and does so quickly,” said Dr. Sabaratnam Arulkumaran, Professor Emeritus of Obstetrics and Gynecology at St. George’s, University of London. I believe it is an innovative solution with the potential to significantly impact how we treat PPH globally.”
Simply inserted into the uterus upon childbirth, the single-use InPress device offers the high potential to dramatically reduce the cost of healthcare as well as the risk of maternal mortality associated with PPH.
Note: Although not commercially available in the US at this time, the initiation of an investigational clinical trial, pending FDA approval, is planned for late 2015.
About InPress Technologies
Located in Mountain View, Calif., InPress Technologies is committed to developing a medical device that will eradicate maternal death caused by postpartum hemorrhage (PPH). With its simple, non-invasive InPress device, the company aims to improve the lives of women around the world. More information on InPress Technologies is available at www.inpresstechnologies.com.